Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 3/20 | 0.49 |
| ▸ | CHRNB2 | P17787 | 7/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 6/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 5/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12539689 | 0.77 | MAOB (0.38) | CYP2A6 | |
| SCHEMBL28934728 | 0.73 | CYP2A6 (0.66) | CYP2A6CHRNB2CHRNA4CYP11B2CHRNA7 | |
| SCHEMBL4071841 | 0.72 | — | — | |
| SCHEMBL12533764 | 0.70 | CYP11B2 (0.67) | CYP2A6CHRNB2CHRNA4CYP11B2CHRNA7 | |
| SCHEMBL12533759 | 0.70 | CYP11B2 (0.67) | CYP2A6CHRNB2CHRNA4CYP11B2CHRNA7 | |
| SCHEMBL12533763 | 0.70 | CYP11B2 (0.67) | CYP2A6CHRNB2CHRNA4CYP11B2CHRNA7 | |
| SCHEMBL12533767 | 0.70 | CYP11B2 (0.67) | CYP2A6CHRNB2CHRNA4CYP11B2CHRNA7 | |
| SCHEMBL3091962 | 0.68 | CYP11B2 (0.58) | CYP2A6CHRNB2CHRNA4CYP11B2CHRNA7 | |
| SCHEMBL3095618 | 0.68 | CYP11B2 (0.58) | CYP2A6CHRNB2CHRNA4CYP11B2CHRNA7 | |
| SCHEMBL27974093 | 0.68 | CHRNB2 (0.49) | CYP2A6CHRNB2CHRNA4CYP11B2CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2406266-B1 | 7-CYCLOALKYLAMINOQUINOLONES AS GSK-3 INHIBITORS | KYORIN SEIYAKU KK (JP) | 2013-12-25 | — | — | EP | disclosed |
| US-8071591-B2 | 7-cycloalkylaminoquinolones as GSK-3 inhibitors | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-12-06 | — | — | US | disclosed |
| US-8071591-B2 | 7-cycloalkylaminoquinolones as GSK-3 inhibitors | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-12-06 | — | — | US | disclosed |
| US-20100234367-A1 | 7-CYCLOALKYLAMINOQUINOLONES AS GSK-3 INHIBITORS | Kyorin Pharmaceuticals Co. Ltd | 2010-09-16 | — | — | US | disclosed |
| US-20100234367-A1 | 7-CYCLOALKYLAMINOQUINOLONES AS GSK-3 INHIBITORS | Kyorin Pharmaceuticals Co. Ltd | 2010-09-16 | — | — | US | disclosed |
| WO-2010104205-A1 | 7-CYCLOALKYLAMINOQUINOLONES AS GSK-3 INHIBITORS | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2010-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234367-A1 | 7-CYCLOALKYLAMINOQUINOLONES AS GSK-3 INHIBITORS | GSK3B, GSK3A, GSKIP | CYP2A6 1675/4885CHRNB2 2894/4885CHRNA4 3258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.